Sangamo Therapeutics (SGMO) Non-Current Receivables (2023 - 2025)
Sangamo Therapeutics (SGMO) has 3 years of Non-Current Receivables data on record, last reported at $14.5 million in Q3 2025.
- For Q3 2025, Non-Current Receivables changed N/A year-over-year to $14.5 million; the TTM value through Sep 2025 reached $14.5 million, changed N/A, while the annual FY2024 figure was $12.8 million, 16.62% down from the prior year.
- Non-Current Receivables reached $14.5 million in Q3 2025 per SGMO's latest filing, roughly flat from $14.5 million in the prior quarter.
- Across five years, Non-Current Receivables topped out at $15.4 million in Q4 2023 and bottomed at $12.8 million in Q4 2024.
- Average Non-Current Receivables over 3 years is $14.1 million, with a median of $14.5 million recorded in 2025.
- The widest YoY moves for Non-Current Receivables: up 16.62% in 2024, down 16.62% in 2024.
- A 3-year view of Non-Current Receivables shows it stood at $15.4 million in 2023, then fell by 16.62% to $12.8 million in 2024, then increased by 13.0% to $14.5 million in 2025.
- Per Business Quant database, its latest 3 readings for Non-Current Receivables were $14.5 million in Q3 2025, $14.5 million in Q2 2025, and $13.3 million in Q1 2025.